Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II azacitidine study for chronic graft-versus-host disease
ISRCTN15649711Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in chronic graft-versus-host disease (cGVHD) and Acute Graft-Versus-Host Disease (aGvHD), sponsored by University of Birmingham. Primary endpoint: Best overall response within 6 months. Started Apr 2016; status: completed.
02
Drugs
azacitidine
03
Conditions
chronic graft-versus-host disease (cGVHD)Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ISRCTN15649711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15649711.